bortezomib / Generic mfg. - LARVOL DELTA

ALACRITY: A phase 1b/2 study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in participants with relapsed or refractory light chain amyloidosis (AL) (ASH 2025) - P1/2 | "Daratumumab+CyBorD (cyclophosphamide, bortezomib, dexamethasone) is approved to treat newly diagnosed AL (ANDROMEDA study), with improved outcomes...This study is registered on ClinicalTrials.gov (NCT07081646). Conclusion This study aims to determine the safety, tolerability, and efficacy of AZD0120 in adult participants with relapsed or refractory AL."

CAR T-Cell Therapy • P1/2 data • Amyloidosis • Hematological Malignancies • Hepatology • Leukemia • Liver Failure • Multiple Myeloma

The role of palliative care in the multidisciplinary treatment of immunoglobulin light chain amyloidosis (ASH 2025) - "Despite improved outcomes with daratumumab and bortezomib-based regimens, early mortality and poor quality of life remain clinically unmet needs. Despite high rates of hematologic response, AL amyloidosis patients are gravely affected by significant symptom burden due to delayed/absent organ recovery and/or treatment-related toxicities. Furthermore, AL amyloidosis patients and their families face critical decisions early in their disease course regarding utilization of advanced therapies, such as RRT or organ transplantation. PC interventions address a broad spectrum of needs—including physical, emotional, and psychosocial support—but referrals often occurred late in the disease course."

Amyloidosis • Anorexia • Hematological Malignancies • Multiple Myeloma • Palliative care • Plasmacytoma • Pulmonary Disease • Solid Organ Transplantation

Real-world impact of high-risk cytogenetics and revised ISS (R2 ISS) on response and survival in multiple myeloma patients treated with various induction regimens: A single-center study from India. (ASH 2025) - "Bortezomib-based triplet regimens, including VRd (bortezomib, lenalidomide, dexamethasone) and VCD (bortezomib, cyclophosphamide, dexamethasone), remain the preferred choices for induction therapy in India...Financial constraints in the indian setting restrict access to novel agents like daratumumab, influencing therapy choices... In this Indian cohort, high-risk cytogenetics and advanced RAISS stages independently predicted poorer survival. R2-ISS offered superior prognostic value over R-ISS. Standard-risk patients had similar outcomes with VRd and VCD, while KRd showed promise in a limited group."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Real-world insights into multiple myeloma management: An analysis of EHR-derived data in the UK and Germany (ASH 2025) - "Most common first-line therapy was daratumumab, lenalidomide, and dexamethasone in Germany (13%), and cyclophosphamide, bortezomib, and dexamethasone (24%) in the UK. The UK and Germany cohorts included 616 and 466 patients, respectively. In both countries, 75% of patients were diagnosed at ISS stage II or III. Cytogenetic testing was reported for 59% of patients in Germany, compared to 60% of the UK cohort, with 1q21 gain/amplification and del13q being the most commonly reported positive tests in both countries."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Temporal trends in treatment patterns and overall survival for multiple myeloma management in Taiwan using the national health insurance claims database (ASH 2025) - "Since then, treatment for MM has continued to evolve, most notably with availability of anti-CD38 monoclonal antibodies such as daratumumab (D). We investigated temporal trends in MM treatment patterns and clinical outcomes from 2013 to 2022, a period encompassing onset of reimbursement for lenalidomide (R) in first line (1L) in patients with transplant-ineligible (TI) MM from February 2020, and D for second line (2L) and beyond from April 2020...Between study periods, VTd use in 1L (approximately 50% of patients) was unchanged, use of V(bortezomib)R-dexamethasone(d) increased from 0-17.59%, and use of regimens containing melphalan and alkylators decreased... The NHIRD provides health insurance for the whole population of Taiwan, allowing complete and longitudinal data collection across all treatment settings. We observed increased uptake of novel agents after their reimbursement under the National Health Insurance that coincided with a decrease in attrition rates and an..."

Claims database • Clinical • Reimbursement • US reimbursement • Hematological Malignancies • Multiple Myeloma

Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens (ASH 2025) - P2 | "Two China-specific physician's choice of therapy (CSPCT) subgroups were created by identifying patients receiving the predominant treatment regimens in China from the identified COTA cohort (CSPCT1: DVd, D-VMP, DKd, IxaDd, DRd, DPd, DRVd, DVTd; CSPCT2: daratumumab + [either carfilzomib or bortezomib or ixazomib] + any non-IMiD). In unweighted analyses vs CSPCT2, ELRA was associated with longer PFS (mPFS, 17.25 vs 4.93 months; HR, 0.55; 95% CI, 0.34-0.89; P <.05), numerically longer OS (mOS, 24.61 vs 14.95 months; HR, 0.70; 95% CI, 0.46-1.08; P =.11), and longer DOR (mDOR, NR vs 4.70 months; HR, 0.17; 95% CI, 0.07-0.41; P <.05). Conclusions Among BCMA-naive patients with RRMM who resemble those from the MM-3 trial, patients treated with ELRA have better outcomes than patients using the predominant treatment regimens available in China."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

Real-world survey of triplet versus quadruplet regimen preferences in transplant-ineligible (TIE) or deferred patients with newly diagnosed (ND) multiple myeloma (MM) (ASH 2025) - P3 | "Recently, data pertaining to anti-CD38 mAb-containing quadruplet regimens have been published (IMROZ: isatuximab ± bortezomib, lenalidomide, and dexamethasone [Isa-VRd]; NCT03319667 and CEPHEUS: daratumumab ± bortezomib, lenalidomide, and dexamethasone [Dara-VRd]; NCT03652064). The real-world data shows that Dara-VRd has emerged as the preferred regimen for non-frail, TIE/deferred patients with ND MM and that DRd is the preferred regimen for frail, TIE patients with ND MM. While interest for Isa-VRd saw a drastic increase for frail TIE patients with ND MM following review of the data, Dara-VRd was still the preferred anti-CD38 regimen if quadruplet regimens were considered. Despite the lack of a subgroup analysis of frail versus non-frail patients from CEPHEUS, Dara-VRd remains the preferred quadruplet therapy over Isa-VRd for TIE/deferred ND MM."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Transplantation

Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States (ASH 2025) - "Treatment regimens were categorized into 7 mutually exclusive groups: bendamustine (B)-based chemotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without cytarabine), Bruton tyrosine kinase inhibitors (BTKi; covalent: zanubrutinib, acalabrutinib, ibrutinib, and non-covalent: pirtobrutinib), bortezomib (bort)-based, venetoclax (ven)-based, intensive chemotherapy (high-dose cytarabine, HyperCVAD (hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone, etc.), and other regimens (CAR-T or others). However, chemotherapy and/or immunotherapy were associated with the highest HCRU while BTKi were associated with the lowest HCRU. Notably, more than half of patients previously treated with BTKi and anti-CD20 therapies were subsequently treated with another covalent BTKi or a non-covalent BTKi, while approximately one-third received chemotherapy and/or immunotherapy, further emphasizing the need for novel..."

Clinical • HEOR • Real-world • Real-world evidence • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

Feasibility assessment of indirect treatment comparison between off-label rituximab and novel treatments in patients with warm autoimmune hemolytic anemia (ASH 2025) - "Among the clinical trials included, five studied rituximab, in combination with prednisone, prednisolone, ibrutinib, or bortezomib. Three trials studied fostamatinib, while other studied treatments included pegcetacoplan, sovleplenib, parsaclisib, and rilzabrutinib...Future work should consider de novo sources of real-world evidence for rituximab that more closely align with registrational trial characteristics and endpoint definitions. However, aligning timing of endpoint measurements between registration trials and real-world data to match definitions remains challenging."

Clinical • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immunology

Disease burden and treatment patterns in patients with previously treated primary immune thrombocytopenia (ITP): A retrospective study using administrative claims data in the United States (ASH 2025) - "Following the initial ITP diagnosis, previously treated patients were identified as those who were currently on ITP treatment and who had received one prior therapy comprising an oral corticosteroid, IVIG, IV anti-D, or platelet transfusion, as well as one or more prior therapies comprising TPO-RA, rituximab, fostamatinib, anti-CD-38 monoclonal antibodies, immunosuppressants, danazol, dapsone, bortezomib, vinca alkaloid, or splenectomy. Conclusions Despite receiving at least one currently available first-line and second-line therapy, in this US-based claims study of patients with primary ITP, a significant proportion continued to experience bleeding events and required rescue therapy. This analysis highlights significant unmet needs for novel therapies for the primary ITP patient population."

Retrospective data • Gynecology • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Administration of chemoterapy at home for "unfit" hematological patients: A safe and cost-effective way. (ASH 2025) - "Materials and During 2022 we provide identification of patients suffering from Myelodysplastic Syndrome, Multiple Myeloma, and Chronic Lymphatic Leukemia requiring chemotherapy and among these the number of patients defined as UNFIT.We activated two projects of home sub cutaneous or oral chemotherapy as follow: PROJECT N° 1:DOMICILIATION OF CHEMOTHERAPY PER ORAL WITH OBLIGATION OF AIFA CARD for patients affected by Multiple Myeloma and Chronic lymphocytic leukemia PROJECT N° 2: DOMICILIATION OF Sub Cutaneos CHEMOTHERAPY for patients affected by Multiple Myeloma in therapy with VELCADE; - Myelodysplastic syndrome in therapy with VIDAZA. The path for the future is set to effectively respond to the ever-increasing needs of patients due to social and demographic changes. The Hematology Department of the Ragusa Local Health Authority intends to continue in this direction, as being treated at home is very different, psychologically and emotionally, from being..."

Clinical • Cost effectiveness • HEOR • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Multiple Myeloma • Myelodysplastic Syndrome

A lean thinking approach to improve efficiency in providing immune-chemotherapy injection in out-patient service: A pivotal study (ASH 2025) - "Thus, room A can be dedicated to longer infusion times (> 2 hours, like CHOP, ABVD, obinotuzumab etc), B room for intermediate therapies (30 min-2 hours, like carfilzomib, decitabine), room D for short therapies (less than 10 minutes, like bispecific antibodies, daratumumab, bortezomib), room C for device maintenance and blood drawing, obtaining a further NVT reduction to 57 minutes but a NVTp worsening to 48%...Based on these scenarios, we developed an integrated software solution with AI functionality based on the automation of infusion station assignment, eliminating the distinction by pathology and length of treatment, reducing the average patient waiting time to 13 minutes, the in-patient stay to 23 minutes for short-term therapies, such as daratumumab and bispecifics, and 45 minutes for intermediate therapies such as isatuximab infusion. Conclusions Our approach proposes leveraging existing infrastructure resources, particularly infusion chairs, which are often..."

Clinical • Hematological Malignancies • Oncology

Administration- and adverse event-related costs among patients with multiple myeloma treated with B-cell maturation antigen (BCMA)-targeted agents (ASH 2025) - " A 3-year BIM was developed to evaluate administration and AE-related costs for patients with RRMM and ≥1 prior line of therapy who had received belamaf plus bortezomib and dexamethasone (BVd), belamaf plus pomalidomide and dexamethasone (BPd), cilta-cel, ide-cel, or teclistamab. BVd/BPd had substantially lower administration and AE-related costs vs CAR-T and bispecific therapies, which have high costs mostly due to hospitalizations, premedication, and CRS rates."

Adverse events • Clinical • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient (ASH 2025) - "Complete remission (CR) was achieved after one cycle of melphalan/prednisone and local radiotherapy, but an abdominal relapse occurred six months later. Despite subsequent lines of therapy (bortezomib(bort)/lenalidomide(lena)/dexamethasone(dexa) and bendamustine/bort/dexa), the extramedullary multiple myeloma (MM) progressed. Remission was achieved after dexa/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE) and an autologous HCT performed on 1/2021...Allogeneic HCT was performed in 8/2022 after fludarabine/melphalan conditioning and anti-thymocyte globulin from a CCR5-Δ32homozygous, unrelated HLA-matched donor; cyclosporine/methotrexate was utilized as graft-versus-host diseas e (GVHD) prophylaxis... To our knowledge, this represents the first report of ART-free HIV RNA suppression following allogeneic HCT with a CCR5Δ32homozygous donor in an individual perinatally infected with HIV. Despite the differences in the latent reservoir and the mechanism..."

Clinical • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Multiple Myeloma • Plasmacytoma • Transplantation • CCR5 • CD4 • CD8

An exploratory study to evaluate the safety and efficacy of autologous CAR-T cells with dual targeting of BCMA and CD19 (FKC289 Injection) in subjects with relapsed or refractory systemic light chain amyloidosis (ASH 2025) - P=N/A | "Although the anti-CD38 monoclonal antibody daratumumab, combined with cyclophosphamide–bortezomib–dexamethasone (Dara-CyBorD), has recently been approved for newly diagnosed AL amyloidosis, effective options remain limited for relapsed/refractory patients (rr-ALA). This preliminary data shows FKC289 is promising in patients with rr-ALA with reaching hematological CR rapidly. Subsequent organ response is expected with long-term follow-up."

CAR T-Cell Therapy • Clinical • Amyloidosis • Hematological Malignancies

High risk MDS in the wke of anti-BCMA CART therapy in refractory multiple myeloma. (ASH 2025) - "Case Report We present the case of a female patient diagnosed with IgG multiple myeloma in 2015, initially treated with induction chemotherapy using lenalidomide, bortezomib, and dexamethasone (RVD), followed by autologous HSCT...She subsequently progressed on a combination of daratumumab, lenalidomide, and dexamethasone. Further disease progression occurred on a regimen of ixazomib, pomalidomide, and dexamethasone. She then achieved a temporary response to carfilzomib, lenalidomide, and dexamethasone, followed by a second autologous HSCT, but relapsed again after approximately one year of maintenance therapy...While this association warrants further investigation, it emphasizes the need for ongoing observation of patients who have received CAR T-cell therapy. Future studies should aim to clarify the potential mechanistic links, including clonal evolution, selective pressures imposed by immunotherapy, and the contribution of prior cytotoxic exposures."

IO biomarker • Acute Lymphocytic Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Cardiomyopathy • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • TP53

CAR-T cell therapy in multiple myeloma in a front-line setting: A systematic review and meta-analysis (ASH 2025) - "Induction therapy regimen before CAR-T included bortezomib, lenalidomide, and dexamethasone (VRd), or clarithromycin, lenalidomide, and dexamethasone (BiRd), or a combination of VRd and bortezomib, doxorubicin, and dexamethasone (PAD). CAR-T cell therapy showed promising rates of overall response and durable remission in newly diagnosed MM patients in a frontline setting. However, the small sample sizes necessitate further trials with large patient populations to enhance our understanding of these outcomes with CAR-T cell therapy in MM."

CAR T-Cell Therapy • Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Neutropenia

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network. (ASH 2025) - "Treatment exposure patterns indicated a heavily pretreated, triple-class refractory population: proteasome inhibitors (bortezomib 61%, carfilzomib 47%), IMiDs (lenalidomide 67%, pomalidomide 69%), and anti-CD38 monoclonal antibodies (daratumumab 67%). Additional therapies included CAR T-cell therapy (8%), autologous stem cell transplant (23%), Belantamab mafodotin (8%), Talquetamab (10%), and Teclistamab (8%)...Tocilizumab was used in 21% of patients... In comparison to the MagnetisMM-3 trial, this real-world analysis confirms the manageable immune toxicity profile of ELRA, with similarly low rates of grade ≥3 CRS and ICANS. However, the higher 6-month mortality (22.6%) observed in this cohort may reflect broader patient inclusion, including those with significant comorbidities and prior BCMA-directed therapies. Hematologic and infectious toxicities were substantial, reinforcing the need for enhanced monitoring and supportive care strategies in routine clinical use."

Real-world • Real-world evidence • Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Influenza • Leukemia • Multiple Myeloma • Nephrology • Neutropenia • Plasma Cell Leukemia • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network. (ASH 2025) - "Treatment patterns reflected a triple-class refractory population, with high prior exposure to proteasome inhibitors (bortezomib 52%, carfilzomib 48%), IMiDs (lenalidomide 66%, pomalidomide 63%), and anti-CD38 antibodies (daratumumab 51%). Additionally, 35% had received CAR T-cell therapy, 39% underwent ASCT, 24% were treated with Teclistamab, and extramedullary disease and plasma cell leukemia were reported in 11% and 13% of patients, respectively...Grade ≥3 CRS and ICANS occurred in <10 patients each (2.4%), and 24% received tocilizumab for CRS... In this large, real-world cohort, Talquetamab demonstrated favorable short-term survival and a manageable safety profile, consistent with clinical trial data. The higher mortality observed may reflect the heavily pretreated, triple-class refractory population with advanced disease features and comorbidities often seen in real-world settings. Hematologic toxicities remained significant, while lower observed rates of..."

Real-world • Real-world evidence • Retrospective data • Dermatology • Multiple Myeloma • Neutropenia • Plasma Cell Leukemia • Thrombocytopenia

A single-center retrospective study of ixazomib-based regimens as maintenance therapy in newly diagnosed multiple myeloma (ASH 2025) - "Induction regimens included VRd (bortezomib-lenalidomide-dexamethasone, 57.4%), DVRd (daratumumab-bortezomib-lenalidomide-dexamethasone, 22.2%), and DVd (daratumumab-lenalidomide-dexamethasone, 9.3%). Notably, it effectively mitigates the adverse impact of high-risk genetic factors, positioning it as an emerging therapeutic option for high-risk NDMM maintenance therapy. Longer follow-up is warranted to confirm sustained survival benefits."

Retrospective data • Cardiovascular • Hematological Disorders • Hematological Malignancies • Hypertension • Multiple Myeloma • Thrombocytopenia

Preliminary analysis of a single-center study on chidamide combined with ICD regimen in bortezomib-exposed relapsed/refractory multiple myeloma patients (ASH 2025) - P2 | "Thus, we aimed to evaluate the efficacy and safety of chidamide combined with the ICD regimen (ixazomib, cyclophosphamide, dexamethasone) in RRMM patients exposed to bortezomib...All patients had received a median of 2 prior lines (range: 1–6), with 100% exposed to bortezomib and 90.9% to lenalidomide, 18.2% to ixazomib, 18.2% to carfilzomib, and 18.2% to daratumumab... Preliminary results demonstrate promising clinical efficacy and manageable safety of chidamide combined with ICD in RRMM patients double-exposed to bortezomib and lenalidomide. Further validation with larger cohorts and longer follow-up is warranted."

Clinical • Hematological Malignancies • Hepatology • Infectious Disease • Liver Failure • Multiple Myeloma • Pneumonia • Respiratory Diseases

autologous hematopoietic cell transplantation (AHCT) in the era of novel therapies for multiple myeloma– real-world data from a single cente (ASH 2025) - "This study evaluates the long-term efficacy and outcomes of AHCT in a real-world cohort of MM patients receiving either daratumumab-based quadruplets or bortezomib-based triplets as induction therapy...Disease status at the time of transplantation showed complete response (CR) in 22 patients (49%) in Group A and 10 patients (28%) in Group B. Stem cell mobilization yielded a median of 3.42×10⁶ CD34⁺ cells/kg (range: 2.00–9.5) vs 4.11×10⁶ cells/kg (range: 2.00–9.3) and plerixafor was required in 59% vs 46% in Groups A and B and respectively .Median time to neutrophil and platelet engraftment was similar to both treatment groups [11 days in both groups for neutrophil (range: 9–13 and 7–13), and 13 days (range: 10–26) vs 11 days (range: 8–23) for platelet in Groups A and B...Conclusion Autologous stem cell transplantation remains an effective treatment option for multiple myeloma, even in the era of novel induction regimens. Daratumumab-based quadruplets do not..."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Plasmacytoma • Transplantation • CD34

Safety and efficacy of daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) in patients with multiple myeloma: A systematic review and meta-analysis. (ASH 2025) - "However, this benefit comes with an increased risk of grade 3–4 neutropenia and thrombocytopenia. No significant differences were observed in complete response or grade 3–4 anemia."

Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

Dara-vd vs vrd: A breakthrough in newly diagnosed multiple myeloma treatment — superior survival and safety profiles (ASH 2025) - P=N/A | "Bortezomib, lenalidomide, and dexamethasone (VRd) is currently a standard option, but it has certain limitations, including limited efficacy in high-risk patients, significant side effects, and restricted applicability in elderly or frail patients. Peripheral edema(1.03% vs 0.93%) and pneumonia rates(4.12% vs 4.67%) were similar. In conclusion, Dara-Vd may be superior to VRd in NDMM, particularly in older patients and those with renal insufficiency, offering favorable deep remission, better PFS trends, and manageable safety."

Clinical • Cardiovascular • Geriatric Disorders • Herpes Zoster • Infectious Disease • Multiple Myeloma • Nephrology • Neutropenia • Pneumonia • Renal Disease • Respiratory Diseases • Thrombocytopenia • Thrombosis • Varicella Zoster

Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma (ASH 2025) - "Treatment regimens consisted of aponermin combined with daratumumab and various backbone therapies: dexamethasone (35.71%), selinexor-dexamethasone (28.57%), bortezomib-dexamethasone (14.29%), lenalidomide-dexamethasone (7.14%), cyclophosphamide-dexamethasone (7.14%), and carfilzomib-dexamethasone (7.14%). No hepatotoxicity was observed throughout the treatment period. Real-world data demonstrate that aponermin and daratumumab-based regimens exhibit promising efficacy and favorable safety profiles in MM patients, particularly in heavily pretreated RRMM patients, offering a potential new treatment option for this challenging population."

Clinical • IO biomarker • Real-world • Real-world evidence • Constipation • Gastroenterology • Gastrointestinal Disorder • Lymphoma • Multiple Myeloma • Thrombocytopenia